Is this your brand? Sign in to claim ownership.

Sign in to claim this brand

Dexcom

United States·US-MF-000010694

Last updated September 17, 2026

Information

Country
United States
Address
6340, Sequence Dr, San Diego, United States
LinkedIn
—
Facebook
—
Phone
1-888-738-3646
PRRC Contact
Rishi Jain
EUDAMED SRN
US-MF-000010694
FDA FEI Number
3004753838
DUNS Number
—

Catalogue (188)

Page 4 of 4
DeviceModel / ReferenceRegistriesClassStatus
Dexcom G6 Transmitter 9445-24
FDA UDI
Class IIActive
Dexcom ONE Continuous Glucose Monitoring System STK-DO-109
EUDAMED
Class IIbActive
Dexcom ONE Continuous Glucose Monitoring System STP-DO-102
EUDAMED
Class IIbActive
Dexcom G7 Continuous Glucose Monitoring System K213919
FDA 510(k)
Class IIActive
Dexcom G6 Continuous Glucose Monitoring (CGM) System K201328
FDA 510(k)
Class IIActive
Dexcom G6 Continuous Glucose Monitoring System K183206
FDA 510(k)
Class IIActive
Dexcom G6 Pro Continuous Glucose Monitoring System K191833
FDA 510(k)
Class IIActive
Studio On The Cloud Data Management Software DEN140016
FDA 510(k)
Class IActive
Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose Program Continuous Glucose Monitoring System and Dexcom Pro Q Continuous Glucose Monitoring System K191450
FDA 510(k)
Class IIActive
Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose Program Continuous Glucose Monitoring System K200876
FDA 510(k)
Class IIActive
Dexcom Smart Basal K252818
FDA 510(k)
Class IIActive
Dexcom Pro Q Continuous Glucose Monitoring System K182405
FDA 510(k)
Class IIActive
Dexcom G6 Continuous Glucose Monitoring (CGM) System, Dexcom G6 Glucose Program Continuous Glucose Monitoring (CGM) System, Dexcom G6 Professional Continuous Glucose Monitoring (CGM) System K221259
FDA 510(k)
Class IIActive
Dexcom G7 Continuous Glucose Monitoring (CGM) System K231081
FDA 510(k)
Class IIActive
Dexcom G6 Continuous Glucose Monitoring (CGM) System K223931
FDA 510(k)
Class IIActive
Dexcom G6 Glucose Program Continuous Glucose Monitoring System K182041
FDA 510(k)
Class IIActive
Dexcom G7 Continuous Glucose Monitoring System K240902
FDA 510(k)
Class IIActive
Dexcom G7 Continuous Glucose Monitoring (CGM) System, Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System K253710
FDA 510(k)
Class IIActive
Dexcom Share Direct Secondary Displays DEN140038
FDA 510(k)
Class IIActive
Dexcom G6 Glucose Program Continuous Glucose Monitoring (CGM) System K203089
FDA 510(k)
Class IIActive
Dexcom G7 Continuous Glucose Monitoring System K234133
FDA 510(k)
Class IIActive
Dexcom G7 Continuous Glucose Monitoring (CGM) System; Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System K253737
FDA 510(k)
Class IIActive
Dexcom G6 Glucose Program Continuous Glucose Monitoring (CGM) System K193642
FDA 510(k)
Class IIActive
Stelo Glucose Biosensor System K234070
FDA 510(k)
Class IIActive
Dexcom G7 15 Day Continuous Glucose Monitoring System K243214
FDA 510(k)
Class IIActive
Dexcom G6 Glucose Program Continuous Glucose Monitoring (GCM) System K192787
FDA 510(k)
Class IIActive
Dexcom G6 Continuous Glucose Monitoring System DEN170088
FDA 510(k)
Class IIActive
Dexcom ONE+ CGM System STP-D7-004
EUDAMED
Class IIbActive
Dexcom ONE Continuous Glucose Monitoring System STP-DO-002
EUDAMED
Class IIbActive
Dexcom ONE+ CGM System STK-D7-109
EUDAMED
Class IIbActive
Dexcom ONE+ CGM System STK-D7-103
EUDAMED
Class IIbActive
Dexcom ONE Continuous Glucose Monitoring System STK-DO-013
EUDAMED
Class IIbActive
Dexcom ONE+ CGM System STE-D7-004
EUDAMED
Class IIbActive
CGM Informed Therapy Adjustment SW14553
EUDAMED
Class IIbActive
Dexcom ONE Continuous Glucose Monitoring System STP-DO-101
EUDAMED
Class IIbActive
Dexcom G5 Mobile Continuous Glucose Monitoring System P120005
FDA PMA
Class IIIActive
Dexcon Seven And Seven Plus P050012
FDA PMA
Class IIIActive
Dexcom ONE+ CGM System STE-D7-002
EUDAMED
Class IIbActive

Related Companies

Authorised Representatives

Importers

Not available yet.

Notified Bodies

Not available yet.

Authorities

Not available yet.

FDA Recalls (28)

Recalls reported by this firm to the FDA. Listed at company level — FDA recall records don't identify a specific catalogue device.

DateRecall No.ClassStatusReason
Apr 14, 2026Z-2165-2026—open, classified

A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the foreground, causing the Glucose Compass to flicker through previous EGVs. In more severe instances, the app may perceive signal loss and deploy signal loss mitigations. This delay in EGV and alert processing creates a risk that users may miss detection of a hypoglycemic or hyperglycemic event, or make treatment decisions based on outdated glucose information.

Apr 14, 2026Z-2164-2026—open, classified

A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the foreground, causing the Glucose Compass to flicker through previous EGVs. In more severe instances, the app may perceive signal loss and deploy signal loss mitigations. This delay in EGV and alert processing creates a risk that users may miss detection of a hypoglycemic or hyperglycemic event, or make treatment decisions based on outdated glucose information.

Apr 14, 2026Z-2163-2026—open, classified

A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the foreground, causing the Glucose Compass to flicker through previous EGVs. In more severe instances, the app may perceive signal loss and deploy signal loss mitigations. This delay in EGV and alert processing creates a risk that users may miss detection of a hypoglycemic or hyperglycemic event, or make treatment decisions based on outdated glucose information.

Aug 28, 2025Z-0318-2026—open, classified

A software defect in version v1.15.0 of the G6 Android app can cause the app to terminate unexpectedly, which may result in the user not receiving estimated glucose values, alarms, alerts or notifications. This could result in the missed detection of a hyperglycemic or hypoglycemic event, protentional resulting in severe hyperglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state (HHS).

Jul 24, 2025Z-2447-2025—open, classified

The affected devices are the Dexcom G7 Continuous Glucose Monitoring System (CGM System) using iOS, watchOS and Android App software (versions 2.8.0 or earlier) and Dexcom ONE+ CGM System using iOS and Android App software (versions 1.4.0 or earlier), henceforth referred to as the App. The affected App does not provide an expected "Sensor Failed" alert when the transmitter sends a "transmitterFailed" error message to the App when the CGM experiences a hardware or firmware failure. Instead, the App ends the CGM sensor session, stops reporting glucose values and displays the Start Sensor screen or No active sensor message without alerting the user, which can lead to missed detection of a hyperglycemic or hypoglycemic event and a delay in treatment.

Jul 24, 2025Z-2446-2025—open, classified

The affected devices are the Dexcom G7 Continuous Glucose Monitoring System (CGM System) using iOS, watchOS and Android App software (versions 2.8.0 or earlier) and Dexcom ONE+ CGM System using iOS and Android App software (versions 1.4.0 or earlier), henceforth referred to as the App. The affected App does not provide an expected "Sensor Failed" alert when the transmitter sends a "transmitterFailed" error message to the App when the CGM experiences a hardware or firmware failure. Instead, the App ends the CGM sensor session, stops reporting glucose values and displays the Start Sensor screen or No active sensor message without alerting the user, which can lead to missed detection of a hyperglycemic or hypoglycemic event and a delay in treatment.

Jul 24, 2025Z-2449-2025—open, classified

The affected devices are the Dexcom G7 Continuous Glucose Monitoring System (CGM System) using iOS, watchOS and Android App software (versions 2.8.0 or earlier) and Dexcom ONE+ CGM System using iOS and Android App software (versions 1.4.0 or earlier), henceforth referred to as the App. The affected App does not provide an expected "Sensor Failed" alert when the transmitter sends a "transmitterFailed" error message to the App when the CGM experiences a hardware or firmware failure. Instead, the App ends the CGM sensor session, stops reporting glucose values and displays the Start Sensor screen or No active sensor message without alerting the user, which can lead to missed detection of a hyperglycemic or hypoglycemic event and a delay in treatment.

Jul 24, 2025Z-2450-2025—open, classified

The affected devices are the Dexcom G7 Continuous Glucose Monitoring System (CGM System) using iOS, watchOS and Android App software (versions 2.8.0 or earlier) and Dexcom ONE+ CGM System using iOS and Android App software (versions 1.4.0 or earlier), henceforth referred to as the App. The affected App does not provide an expected "Sensor Failed" alert when the transmitter sends a "transmitterFailed" error message to the App when the CGM experiences a hardware or firmware failure. Instead, the App ends the CGM sensor session, stops reporting glucose values and displays the Start Sensor screen or No active sensor message without alerting the user, which can lead to missed detection of a hyperglycemic or hypoglycemic event and a delay in treatment.

Jul 24, 2025Z-2448-2025—open, classified

The affected devices are the Dexcom G7 Continuous Glucose Monitoring System (CGM System) using iOS, watchOS and Android App software (versions 2.8.0 or earlier) and Dexcom ONE+ CGM System using iOS and Android App software (versions 1.4.0 or earlier), henceforth referred to as the App. The affected App does not provide an expected "Sensor Failed" alert when the transmitter sends a "transmitterFailed" error message to the App when the CGM experiences a hardware or firmware failure. Instead, the App ends the CGM sensor session, stops reporting glucose values and displays the Start Sensor screen or No active sensor message without alerting the user, which can lead to missed detection of a hyperglycemic or hypoglycemic event and a delay in treatment.

May 12, 2025Z-1946-2025—open, classified

Defective foam or an assembly error may cause the receiver speaker to lose contact with the printed circuit board, leading to missed audible alerts for low or high blood glucose values. A missed audible alert for low or high blood glucose values could lead to untreated hypo or hyperglycemia which can cause seizures, vomiting, loss of consciousness, or death.

May 12, 2025Z-1943-2025—open, classified

Defective foam or an assembly error may cause the receiver speaker to lose contact with the printed circuit board, leading to missed audible alerts for low or high blood glucose values. A missed audible alert for low or high blood glucose values could lead to untreated hypo or hyperglycemia which can cause seizures, vomiting, loss of consciousness, or death.

May 12, 2025Z-1944-2025—open, classified

Defective foam or an assembly error may cause the receiver speaker to lose contact with the printed circuit board, leading to missed audible alerts for low or high blood glucose values. A missed audible alert for low or high blood glucose values could lead to untreated hypo or hyperglycemia which can cause seizures, vomiting, loss of consciousness, or death.

May 12, 2025Z-1945-2025—open, classified

Defective foam or an assembly error may cause the receiver speaker to lose contact with the printed circuit board, leading to missed audible alerts for low or high blood glucose values. A missed audible alert for low or high blood glucose values could lead to untreated hypo or hyperglycemia which can cause seizures, vomiting, loss of consciousness, or death.

May 5, 2025Z-1906-2025—open, classified

A bug in the 2.7.0 version of the G7 iOS App can cause the app to enter a state where it stops updating the estimated glucose value (EGV) and continues to show this stale EGV. If the user is unaware that the EGVs are not being updated and that glucose alerts will not trigger, there is potential for the missed detection of a hyperglycemic or hypoglycemic event or a treatment decision made based off incorrect data. There is no impact to transmitter communication with concurrently connected displays. A concurrently connected receiver, Apple Watch, and/or insulin pump will continue to receive EGVs directly from the transmitter when the app is in the problematic state. There is no impact to Automated Insulin Dosing (AID) therapy as the AID system continues to receive EGVs directly from the transmitter.

Jan 27, 2025Z-1203-2025—open, classified

Under very rare situations, the Dexcom G6 touchscreen receiver may not provide high or low glucose alarms/alerts as designed, which can result in two different conditions. First, if a receiver operating system .net error occurs when an alarm/alert should be triggered, the initial alarm/alert will not be delivered until a subsequent alarm/alert is triggered. At that time, the initial alarm/alert is delivered, but not the second one. Alarm/alerts will continue to be delayed and be one alarm/alert behind, causing delayed alarm/alerts until the receiver is reset. This condition could result in the missed detection of a hyperglycemic or hypoglycemic event. Second, a single EGV reading may be delayed for 5 minutes after the initial .net operating system error. If the user receives a single EGV reading delayed by 5 minutes, the delay is not expected to cause user harm.

Jan 27, 2025Z-1204-2025—open, classified

Under very rare situations, the Dexcom G6 touchscreen receiver may not provide high or low glucose alarms/alerts as designed, which can result in two different conditions. First, if a receiver operating system .net error occurs when an alarm/alert should be triggered, the initial alarm/alert will not be delivered until a subsequent alarm/alert is triggered. At that time, the initial alarm/alert is delivered, but not the second one. Alarm/alerts will continue to be delayed and be one alarm/alert behind, causing delayed alarm/alerts until the receiver is reset. This condition could result in the missed detection of a hyperglycemic or hypoglycemic event. Second, a single EGV reading may be delayed for 5 minutes after the initial .net operating system error. If the user receives a single EGV reading delayed by 5 minutes, the delay is not expected to cause user harm.

Jan 27, 2025Z-1202-2025—open, classified

Under very rare situations, the Dexcom G6 touchscreen receiver may not provide high or low glucose alarms/alerts as designed, which can result in two different conditions. First, if a receiver operating system .net error occurs when an alarm/alert should be triggered, the initial alarm/alert will not be delivered until a subsequent alarm/alert is triggered. At that time, the initial alarm/alert is delivered, but not the second one. Alarm/alerts will continue to be delayed and be one alarm/alert behind, causing delayed alarm/alerts until the receiver is reset. This condition could result in the missed detection of a hyperglycemic or hypoglycemic event. Second, a single EGV reading may be delayed for 5 minutes after the initial .net operating system error. If the user receives a single EGV reading delayed by 5 minutes, the delay is not expected to cause user harm.

Feb 3, 2020Z-1562-2020—terminated

The company identified potential interference from hydroxyurea. Patient use of the anti-neoplastic drug may falsely elevate glucose readings on the Continuous Glucose Monitoring Systems.

Feb 3, 2020Z-1560-2020—terminated

The company identified potential interference from hydroxyurea. Patient use of the anti-neoplastic drug may falsely elevate glucose readings on the Continuous Glucose Monitoring Systems.

Feb 3, 2020Z-1561-2020—terminated

The company identified potential interference from hydroxyurea. Patient use of the anti-neoplastic drug may falsely elevate glucose readings on the Continuous Glucose Monitoring Systems.

Nov 19, 2019Z-1104-2020—terminated

It was reported that the user's low alarm feature on the iOS application were not properly alerting users when the user has enabled the Alert Schedule feature more than 30 days after installing the iOS application.

Jul 12, 2019Z-0929-2020—terminated

It has been reported that use of the mobile receiver with software version SW10617 rev 4.0.1.048 have reported: 1. the receiver becoming stuck on initialization screen when powering on. This will cause patients not to be able to receive glucose values or alerts; 2. Reinitialization of the receiver without user interaction. If this occurs, the receiver will either reboot and operate normally or require the user to press the Select button on the receiver in order to resume normal operation. In this situation, the user is provided an audio and vibratory alert every 5 minutes. Until the select button is pressed, patients will not receive glucose values or alerts.

Feb 23, 2016Z-1339-2016—terminated

Customers may not receive an intended audible alarm or alert if relying on hearing the alarm or alert.

Feb 23, 2016Z-1337-2016—terminated

Customers may not receive an intended audible alarm or alert if relying on hearing the alarm or alert.

Feb 23, 2016Z-1338-2016—terminated

Customers may not receive an intended audible alarm or alert if relying on hearing the alarm or alert.

Feb 23, 2016Z-1334-2016—terminated

Customers may not receive an intended audible alarm or alert if relying on hearing the alarm or alert.

Feb 23, 2016Z-1336-2016—terminated

Customers may not receive an intended audible alarm or alert if relying on hearing the alarm or alert.

Feb 23, 2016Z-1335-2016—terminated

Customers may not receive an intended audible alarm or alert if relying on hearing the alarm or alert.